Instil Bio, Inc. Interest Expense Nonoperating
Instil Bio, Inc. (TIL) reported Interest Expense Nonoperating of $1.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- Instil Bio, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $1.58M, a 0.00% change year-over-year.
- Instil Bio, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.55M, a 41.35% increase year-over-year.
- Instil Bio, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.57M, a 47.84% decline year-over-year.
- Instil Bio, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.58M, a 21.18% decline year-over-year.
- Instil Bio, Inc. interest expense nonoperating for fiscal 2025 was $5.83M, a 35.18% decline from fiscal 2024.
- Instil Bio, Inc. interest expense nonoperating for fiscal 2024 was $8.99M, a 72.62% increase from fiscal 2023.
- Instil Bio, Inc. interest expense nonoperating for fiscal 2023 was $5.21M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.58M 10-Q · filed 2026-08-13 | $3.13M 10-Q · filed 2026-08-13 | $4.70M derived: sum of 3 quarters · filed 2026-08-13 | $6.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.55M 10-Q · filed 2026-05-15 | $3.12M derived: sum of 2 quarters · filed 2026-05-15 | $4.70M derived: sum of 3 quarters · filed 2026-05-15 | $6.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.15M derived: sum of 2 quarters · filed 2026-03-27 | $4.73M derived: sum of 3 quarters · filed 2026-08-13 | $5.83M 10-K · filed 2026-03-27 |
| 2025-09-30 | $1.58M 10-Q · filed 2025-11-13 | $3.16M derived: sum of 2 quarters · filed 2026-08-13 | $4.26M 10-Q · filed 2025-11-13 | $7.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.58M 10-Q · filed 2026-08-13 | $2.68M 10-Q · filed 2026-08-13 | $5.68M derived: sum of 3 quarters · filed 2026-08-13 | $7.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-15 | $4.10M derived: sum of 2 quarters · filed 2026-05-15 | $6.11M derived: sum of 3 quarters · filed 2026-05-15 | $8.11M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.01M derived: sum of 2 quarters · filed 2026-03-27 | $7.01M derived: sum of 3 quarters · filed 2026-03-27 | $8.99M 10-K · filed 2026-03-27 |
| 2024-09-30 | $2.01M 10-Q · filed 2025-11-13 | $4.01M derived: sum of 2 quarters · filed 2025-11-13 | $5.99M 10-Q · filed 2025-11-13 | $7.97M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-13 | $3.98M 10-Q · filed 2025-08-13 | $5.96M derived: sum of 3 quarters · filed 2025-08-13 | $7.96M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.98M 10-Q · filed 2025-05-13 | $3.96M derived: sum of 2 quarters · filed 2025-05-13 | $5.96M derived: sum of 3 quarters · filed 2025-05-13 | $6.55M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.98M derived: sum of 2 quarters · filed 2025-03-04 | $4.57M derived: sum of 3 quarters · filed 2025-03-04 | $5.21M 10-K · filed 2025-03-04 |
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-13 | $2.59M derived: sum of 2 quarters · filed 2024-11-13 | $3.23M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $590.00K 10-Q · filed 2024-08-13 | $1.23M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |